![](images/null.gif) |
![](images/null.gif) |
![](images/null.gif) |
|
NGM282 Maintains a Durable Off-Treatment Response on Hepatic Steatosis, Inflammation and Fibrogenesis in Patients with Biopsy-Confirmed Nonalcoholic Steatohepatitis: Results of a Multi-Center Phase 2 Dose-Finding Study
|
|
|
Reported by Jules Levin
AASLD 2018 Nov 9-13 SF
Angelo H. Paredes1, James F. Trotter2, Mustafa R. Bashir3, Guy W. Neff 4, Manal F. Abdelmalek5, Grisell Ortiz-Lasanta6, Mark J. Jaros7, Bryan A. Baxter8, Lei Ling8, Stephen J. Rossi8, Alex M. DePaoli8, Stephen A. Harrison9
![1212181](../images%20/121218/121218-2/1212181.gif)
![1212182](../images%20/121218/121218-2/1212182.gif)
![1212183](../images%20/121218/121218-2/1212183.gif)
![1212184](../images%20/121218/121218-2/1212184.gif)
![1212185](../images%20/121218/121218-2/1212185.gif)
![1212186](../images%20/121218/121218-2/1212186.gif)
![1212187](../images%20/121218/121218-2/1212187.gif)
![1212188](../images%20/121218/121218-2/1212188.gif)
|
|
|
![](images/null.gif) |
![](images/null.gif) |
|
|